← Back to Home

Multiple targets in one drug: Zealand partners with Generate to develop AI-designed metabolic therapies

The collaboration will begin with two multispecific protein programs, exploring new treatment approaches for obesity and other metabolic diseases. Nearly $1.2 billion in potential milestone payments indicates the scale of the commitment, but these designs have yet to produce clinical efficacy results.

By SURL BioNews

Could a single drug that acts on several biological targets simultaneously offer better treatment for obesity and metabolic diseases? Zealand Pharma and Generate Biomedicines announced a collaboration on October 13 to design multispecific protein therapies using generative AI, bringing this concept into drug development. The announcement concerns a collaboration and licensing agreement; no human efficacy results for the programs have yet been provided.

“Multispecific” means giving a single protein drug the ability to act on multiple targets. Reuters also identified this as the core of the collaboration. However, the companies have not disclosed the specific target combinations for the two initial programs, so it is not yet possible to determine which metabolic pathways they will affect or how they will differ from existing therapies.

AI’s role here is to help design candidate proteins with predetermined biological functions. Generate’s platform combines generative AI with high-throughput experimental validation, then uses experimental data to refine the designs. This means that molecules proposed by computers must still undergo experimental screening. The announcement did not disclose test results for these two programs, model training data, or candidate molecule performance, leaving insufficient information to assess the platform’s actual effectiveness in this collaboration.

The division of development responsibilities has been established: Generate will lead research through the selection of lead candidate molecules; Zealand will then take over subsequent clinical development, regulatory submissions, and global commercialization. Nordic Life Science noted that Zealand also has an option to add a third program, but the collaboration will begin with two programs.

Under the agreement, Generate will receive a $30 million upfront payment, plus up to $35 million in early preclinical milestone payments. Total potential milestone payments for the two initial programs approach $1.2 billion, covering development, regulatory, and commercial stages; if products reach the market, Generate will also receive tiered sales royalties. These subsequent payments depend on achievements at each stage and are not funds already secured at signing.

For Zealand, which is known for its expertise in peptide research and development, the collaboration also expands the drug modalities available to it. Nordic Life Science interpreted the deal as a step toward expanding the company’s capabilities beyond peptides. Its scientific significance lies in broadening the scope for designing and combining biological functions, but the ability to combine functions does not mean efficacy and safety will both improve.

The questions that now need to be answered are whether the candidate proteins can consistently demonstrate their intended effects in experiments and then show benefits and acceptable risks in human trials. How the multitarget designs affect dosing, the balance of effects, and long-term safety must all be clarified by subsequent data. This agreement establishes a collaborative framework for moving from molecular design to clinical development, but multiple stages of validation remain before these therapies can be available to patients.

References

  1. Generate Biomedicines
  2. Reuters via Euronext
  3. Nordic Life Science